Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis

被引:49
|
作者
Amadori, Anna [1 ]
Antonelli, Andrea [1 ]
Balteri, Ilaria [1 ]
Schreiber, Anja [1 ]
Bugiani, Massimiliano [2 ]
De Rose, Virginia [1 ]
机构
[1] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Resp Dis Div, I-10043 Turin, Italy
[2] Local Hlth Agcy 4, Unit Resp Dis, Turin, Italy
关键词
Cystic fibrosis in adults; Exacerbations; FEV1; decline; PULMONARY-FUNCTION; LUNG-FUNCTION; DIABETES-MELLITUS; COMPUTED-TOMOGRAPHY; NUTRITIONAL-STATUS; ASPERGILLOSIS; SURVIVAL; CHILDREN; THERAPY;
D O I
10.1016/j.rmed.2008.09.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To identify risk factors contributing to FEV1 decline in CF patients, we carried out a retrospective analysis of clinical and pulmonary function data in a population of CF patients followed up for 5 years and studied the correlation between clinical data and FEV1 decline. Fifty-one adult CF patients were studied. The FEV1 decline was related to the following clinical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline FEV1, pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes, number of exacerbations/year and intravenous (i.v.) antibiotic courses/year. Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were strongly related to the FEV1 decline. Patients with airway infection or with diabetes had significantly lower FEV1 values during the study as compared with non-infected patients or patients without diabetes; however, both the presence of airway infection or diabetes did not affect the FEV1 decline. These results suggest that the aggressive treatment of disease exacerbations is crucial for delaying lung function decline in CF. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:407 / 413
页数:7
相关论文
共 50 条
  • [1] Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
    Konstan, Michael W.
    Wagener, Jeffrey S.
    VanDevanter, Donald R.
    Pasta, David J.
    Yegin, Ashley
    Rasouliyan, Lawrence
    Morgan, Wayne J.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) : 405 - 411
  • [2] Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study
    Taylor-Robinson, David
    Whitehead, Margaret
    Diderichsen, Finn
    Olesen, Hanne Vebert
    Pressler, Tania
    Smyth, Rosalind L.
    Diggle, Peter
    THORAX, 2012, 67 (10) : 860 - 866
  • [3] Cystic fibrosis patients at risk for disease progression marked by decline in FEV1% predicted: development of the cystic fibrosis risk of disease progression score
    Marsteller, Nathan L.
    Nussbaum, Eliezer
    Morphew, Tricia
    Randhawa, Inderpal S.
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5557 - 5565
  • [4] The predictive role of lung clearance index on FEV1 decline in cystic fibrosis
    Ozsezen, Beste
    Yalcin, Ebru
    Emiralioglu, Nagehan
    Unlu, Hande Konsuk
    Tural, Dilber Ademhan
    Caka, Canan
    Sunman, Birce
    Dogru, Deniz
    Ozcelik, Ugur
    Kiper, Nural
    TURKISH JOURNAL OF PEDIATRICS, 2024, 66 (03) : 297 - 308
  • [5] Sputum Candida albicans Presages FEV1 Decline and Hospital-Treated Exacerbations in Cystic Fibrosis
    Chotirmall, Sanjay H.
    O'Donoghue, Elaine
    Bennett, Kathleen
    Gunaratnam, Cedric
    O'Neill, Shane J.
    McElvaney, Noel G.
    CHEST, 2010, 138 (05) : 1186 - 1195
  • [6] Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline
    Barboza de Aquino, Carolina Silva
    Rodrigues, Joaquim Carlos
    Ferreira da Silva-Filho, Luiz Vicente Ribeiro
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2022, 48 (03)
  • [7] Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry
    Kerem, Eitan
    Viviani, Laura
    Zolin, Anna
    MacNeill, Stephanie
    Hatziagorou, Elpis
    Ellemunter, Helmut
    Drevinek, Pavel
    Gulmans, Vincent
    Krivec, Uros
    Olesen, Hanne
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (01) : 125 - 133
  • [8] Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States
    Ramos, Kathleen J.
    Quon, Bradley S.
    Heltshe, Sonya L.
    Mayer-Hamblett, Nicole
    Lease, Erika D.
    Aitken, Moira L.
    Weiss, Noel S.
    Goss, Christopher H.
    CHEST, 2017, 151 (06) : 1320 - 1328
  • [9] Clinical Use of Dornase Alfa Is Associated With a Slower Rate of FEV1 Decline in Cystic Fibrosis
    Konstan, Michael W.
    Wagener, Jeffrey S.
    Pasta, David J.
    Millar, Stefanie J.
    Jacobs, Joan R.
    Yegin, Ashley
    Morgan, Wayne J.
    PEDIATRIC PULMONOLOGY, 2011, 46 (06) : 545 - 553
  • [10] Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis
    Konstan, Michael W.
    Schluchter, Mark D.
    Xue, Wei
    Davis, Pamela B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (11) : 1084 - 1089